IVD Assay Development
Seraseq® Breast CNV Mix, + 12 copies
Details
Resources
Specifications
Frequently Asked Questions
Copy number variations (CNV) are genomic changes that lead to higher (amplification) or lower (loss) gene copies in comparison to a reference genome. Cells that are affected by aberrant copy number changes for certain cancer-associated genes may experience disruption of normal cellular function and, ultimately, tumorigenesis. Next-generation sequencing (NGS) can be used to determine CNVs across multiple genes in a sequencing run. However, without a widely adopted standard for CNV profiling, NGS assays may evaluate dosage for different targets using different wet and dry methods. In response, SeraCare has developed the first disease-specific CNV reference materials to support clinical labs performing NGS-based tumor profiling of breast cancer patient samples.
- Single sample with three clinically-relevant CNVs (save acquisition and sequencing costs)
- Develop, optimize, and validate your assay’s ability to detect a range of copy numbers (amplifications)
- CNV targets precisely quantitated with digital PCR
- Single well-characterized GM24385 human genomic DNA as background wild-type material
- Manufactured in GMP-compliant, ISO 13485-certified facilities
This specific CNV Mix for breast cancer includes 12 copies.
Seraseq Mix Safety Data Sheet (Non-Requirement Letter)
Seraseq Breast CNV Mix
Seraseq Breast CNV Mix Package Insert
Seraseq Breast CNV Mix, +12 copies
Seraseq Copy Number Variation (CNV) Reference Materials
Seraseq Breast CNV Mix, +12 copies
Seraseq Breast CNV Mix, +12 copies
Seraseq Breast CNV Mix, +12 copies
Product Specifications | |
# of CNVs | 3 (full gene region for ERBB2, FGFR3, and MYC) |
Copy Numbers | +12 copies (or 14 total copies) of each gene |
Concentration | 10 ng/µL |
Amount | 200 ng (single vial) |
Buffer | 1 mM Tris / 0.1 mM EDTA pH 8.0 |
Solid Tumor FAQs
Review the common questions we receive from our customers and the responses we provide.